文献速递胸部肿瘤放疗放疗物理与技术

同步早期非小细胞肺癌的根治性管理:SABR的疗效与失败模式

Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-02-07

本研究回顾2005至2015年间82例同步早期NSCLC患者(共169个病灶),其中57例(69.5%)接受所有部位SABR。中位OS和PFS分别为5.1年和2.7年,3年OS 67%、5年OS 52%,无≥3级不良事件。SABR对同步早期NSCLC有效且可行,同侧同步病变与区域和远处失败风险更高相关。

要点

  • 同步早期NSCLC患者接受SABR后中位OS 5.1年、PFS 2.7年,≥3级不良事件未见。
  • 57例(69.5%)接受所有部位SABR,全部位SABR与部分SABR在OS、PFS、局控和毒性上无差异。

核心结论

  • 同步早期NSCLC可通过根治性局部治疗管理,SABR控制率高、结局良好,是有效可行的治疗选择。

研究设计与样本

  • 回顾性研究纳入2005至2015年间≥2个同步NSCLC肿瘤(T1a-T2b)且至少1个病灶接受SABR的患者,共82例(占同期912例的9%),169个病灶,中位随访58个月。

主要发现

  • 中位OS和PFS分别为5.1年和2.7年,3年和5年OS分别为67%和52%,对应PFS分别为47%和29%。
  • 142个SABR治疗部位中,6个(4%)野内复发、4个(3%)边缘复发,无≥3级不良事件。

关键数值与推荐

  • 同步病变定义为6个月内诊断的多发同侧或对侧肺内病变。
  • 最常见处方剂量为50 Gy分4次或70 Gy分10次。

临床怎么用

  • 对不可切除的同步早期NSCLC,SABR可作为根治性局部治疗选择,尤其适用于多学科评估后适合的患者。
  • 同侧同步病变患者应加强区域和远处失败的监测与随访。

局限性

  • 回顾性单中心研究,仅82例同步病变患者,部分患者未对所有部位行SABR,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Management of synchronous early-stage non-small cell lung cancer (NSCLC) remains controversial because resection is not always feasible. This study evaluates efficacy and patterns of failure after SABR for synchronous early-stage NSCLC. METHODS AND MATERIALS: From 2005 to 2015, patients presenting with ≥2 synchronous NSCLC tumors (T1a-T2b) and receiving SABR to ≥1 lesion were reviewed. The most common prescriptions were 50 Gy in 4 or 70 Gy in 10 fractions. Patients underwent multidisciplinary management with workup including chest computed tomography and positron emission tomography/computed tomography, plus brain imaging and endoscopic bronchial ultrasound for most patients to rule out mediastinal and distant disease. Synchronous lesions were defined as multiple ipsilateral or contralateral intrapulmonary lesions diagnosed within 6 months. RESULTS: Of 912 patients treated with SABR for early-stage NSCLC at our institution, 82 (9%) presented with synchronous disease, with a total of 169 lesions. SABR was delivered to 142 lesions (84%), with 57 patients (69.5%) receiving SABR for all sites. Median overall survival (OS) and progression-free survival (PFS) were 5.1 and 2.7 years, respectively. At a median follow-up of 58 months, OS was 67% and 52% at 3 and 5 years, and corresponding PFS was 47% and 29%. Thirty-nine patients (48%) had progression, with 21 (26%) experiencing distant failure, and intralobar recurrence was among the first failure for 15 patients (18%). Of the 142 SABR-treated sites, these included 6 in-field (4%) and 4 marginal (3%) recurrences. There were no grade ≥3 adverse events. Among patients receiving SABR for all sites, there were no differences in OS (P = .946), PFS (P = .980), local control (P = .683), regional and distant control (P = .656), or toxicity (P = .791). On multivariable analysis, ipsilateral synchronous disease was associated with greater regional and distant failure (hazard ratio, 2.691; P = .025). CONCLUSIONS: Synchronous NSCLC can be managed with definitive local therapy. With high control rates and favorable outcomes, SABR is an effective and feasible treatment for synchronous early-stage NSCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ayoub Z, Ning MS, Brooks ED, et al. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32044413. doi:10.1016/j.ijrobp.2020.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。